AVRO vs. BLRX, SABS, BYSI, VTVT, BCLI, LIAN, ASMB, ACST, LPCN, and TCRT
Should you be buying AVROBIO stock or one of its competitors? The main competitors of AVROBIO include BioLineRx (BLRX), SAB Biotherapeutics (SABS), BeyondSpring (BYSI), vTv Therapeutics (VTVT), Brainstorm Cell Therapeutics (BCLI), LianBio (LIAN), Assembly Biosciences (ASMB), Acasti Pharma (ACST), Lipocine (LPCN), and Alaunos Therapeutics (TCRT). These companies are all part of the "medical" sector.
BioLineRx (NASDAQ:BLRX) and AVROBIO (NASDAQ:AVRO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, community ranking, profitability, analyst recommendations, risk, dividends and earnings.
BioLineRx received 331 more outperform votes than AVROBIO when rated by MarketBeat users. Likewise, 73.32% of users gave BioLineRx an outperform vote while only 66.93% of users gave AVROBIO an outperform vote.
In the previous week, BioLineRx had 2 more articles in the media than AVROBIO. MarketBeat recorded 3 mentions for BioLineRx and 1 mentions for AVROBIO. AVROBIO's average media sentiment score of 0.00 equaled BioLineRx'saverage media sentiment score.
1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 62.6% of AVROBIO shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by insiders. Comparatively, 9.2% of AVROBIO shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
BioLineRx currently has a consensus price target of $21.00, suggesting a potential upside of 3,400.00%. AVROBIO has a consensus price target of $2.00, suggesting a potential upside of 68.78%. Given AVROBIO's stronger consensus rating and higher probable upside, equities research analysts clearly believe BioLineRx is more favorable than AVROBIO.
BioLineRx's return on equity of -74.86% beat AVROBIO's return on equity.
BioLineRx has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, AVROBIO has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.
AVROBIO has lower revenue, but higher earnings than BioLineRx. AVROBIO is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.
Summary
BioLineRx beats AVROBIO on 9 of the 15 factors compared between the two stocks.
Get AVROBIO News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
